Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

Trial Profile

A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAMILLA
  • Most Recent Events

    • 20 Jan 2024 Results (n=29 of the phase II G/E adenocarcinoma cohort) assessing safety and efficacy of of cabozantinib (cabo) plus durvalumab (durva) in chemotherapy refractory microsatellite stable patients with advanced gastric and esophageal adenocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium
    • 11 Jul 2023 Planned End Date changed from 30 Jun 2024 to 30 Dec 2025.
    • 11 Jul 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top